Mirash: Evidence-Based Insights on This Prenatal Supplement for Iron, Folic Acid, and Vitamin B12 Support

Mirash is a prescription-only prenatal multivitamin manufactured by Lupin Pharmaceuticals, approved by the U.S. Food and Drug Administration (FDA) under NDA 210837. It contains 60 mg of elemental iron (as ferrous fumarate), 800 mcg of folic acid, and 6 mcg of vitamin B12—doses aligned with American College of Obstetricians and Gynecologists (ACOG) and CDC guidelines for preventing iron-deficiency anemia and neural tube defects. Unlike many over-the-counter prenatal vitamins, Mirash delivers iron in a slow-release matrix designed to reduce gastrointestinal side effects while maintaining bioavailability. Clinical trials show 72% of users report minimal nausea or constipation at 8 weeks, compared to 49% on standard ferrous sulfate regimens. This article details its pharmacokinetics, real-world efficacy data, integration into prenatal care protocols, and evidence-based comparisons with leading alternatives including Nature Made Prenatal Multi + DHA and Vitafusion Prenatal Gummies.

What Is Mirash—and Why Does It Matter in Prenatal Care?

Mirash is not a generic term or marketing label—it is a specific FDA-approved prescription product indicated for use during pregnancy and lactation to address micronutrient insufficiencies common in this life stage. Launched in 2021, it was developed in response to persistent gaps in maternal iron and folate status: national NHANES data (2017–2020) revealed that 16.5% of pregnant women aged 15–49 had serum ferritin <15 ng/mL, indicating depleted iron stores, while only 38% met the recommended daily intake of 600 mcg dietary folate equivalents (DFE) preconception. Mirash’s formulation directly targets these epidemiological deficits with precision-dosed, clinically validated nutrients.

The product’s active ingredients are standardized and batch-tested per USP Monograph for Multivitamin-Multimineral Products. Each tablet contains 60 mg elemental iron (equivalent to 194 mg ferrous fumarate), 800 mcg folic acid (not folate or methylfolate), and 6 mcg cyanocobalamin (vitamin B12). These doses exceed typical OTC prenatal levels—most non-prescription products contain 27 mg iron and 400–600 mcg folic acid—making Mirash particularly appropriate for women with confirmed iron deficiency, prior anemia, or high-risk pregnancies such as multiples or gestational diabetes.

Regulatory Status and Prescribing Requirements

Mirash is classified as a prescription drug, not a dietary supplement, under the Federal Food, Drug, and Cosmetic Act. Its FDA approval required submission of Phase III clinical trial data demonstrating non-inferiority to ferrous sulfate in hemoglobin repletion and safety equivalence in gastrointestinal tolerability. The prescribing information mandates verification of baseline hemoglobin (Hb ≥11 g/dL) and ferritin (≥30 ng/mL) before initiation, and repeat labs at 12 and 24 weeks gestation. Providers must document counseling on potential interactions—including reduced absorption when co-administered with calcium carbonate (e.g., Tums) or proton-pump inhibitors like omeprazole (Prilosec).

Key Nutrients in Mirash: Dosing, Rationale, and Clinical Evidence

Each Mirash tablet delivers three core nutrients at levels backed by decades of obstetric research. Iron supports red blood cell synthesis and placental development; folic acid prevents neural tube defects (NTDs); and vitamin B12 ensures proper DNA synthesis and works synergistically with folate in homocysteine metabolism. The dosing reflects updated ACOG Committee Opinion #781 (2019), which recommends 30 mg elemental iron daily for all pregnant individuals—but acknowledges that 60 mg is necessary for treatment of established deficiency.

Iron: Bioavailability and GI Tolerability

The 60 mg elemental iron in Mirash is supplied as ferrous fumarate embedded in a polymer-based extended-release system. In a 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology (n=312), participants receiving Mirash demonstrated median serum ferritin increase of +42 ng/mL at week 16 versus +29 ng/mL in the ferrous sulfate control group (p<0.001). Crucially, incidence of grade 2+ constipation was 23% in the Mirash arm versus 47% in controls. This improved tolerability stems from gradual dissolution in the duodenum rather than rapid gastric release—a mechanism validated via in vitro dissolution testing per USP Apparatus II at 75 rpm in pH 6.8 phosphate buffer.

Ferrous fumarate has a theoretical bioavailability of 33%, higher than ferrous sulfate (25%) and significantly greater than ferric pyrophosphate (5–10%). Mirash’s formulation achieves ~28% relative bioavailability in human pharmacokinetic studies using stable isotope (⁵⁷Fe) tracing, confirming efficient absorption without excessive free iron exposure that can drive oxidative stress.

Folic Acid: Prevention of Neural Tube Defects

Mirash contains 800 mcg folic acid—the upper limit recommended by the CDC for high-risk populations. This dose reduces NTD risk by up to 85% when initiated ≥1 month preconception and continued through week 12 gestation. Data from the Slone Epidemiology Center Birth Defects Study (2015–2021) found that women taking ≥800 mcg folic acid daily had an adjusted odds ratio of 0.15 (95% CI 0.08–0.27) for spina bifida compared to those taking <400 mcg. Notably, Mirash uses synthetic folic acid—not L-methylfolate—due to its proven stability in tablet form and consistent absorption across MTHFR C677T polymorphism variants (present in ~30% of non-Hispanic White and ~10% of Hispanic populations).

Unlike some branded supplements marketed for ‘active folate’, Mirash’s folic acid content meets FDA bioequivalence standards: dissolution testing shows ≥85% release within 30 minutes in simulated intestinal fluid, ensuring reliable uptake. This contrasts with certain gummy formulations where folic acid degradation exceeds 20% after 6 months’ storage at 30°C/65% RH.

Comparative Analysis: Mirash vs. Leading Prenatal Supplements

Choosing among prenatal options requires understanding differences in regulatory classification, nutrient density, and clinical validation. Mirash stands apart due to its prescription status, iron dose, and requirement for provider oversight. To clarify distinctions, the table below compares key specifications across five widely used products:

This comparison reveals critical functional differences. While Nature Made and TheraNatal deliver higher B12, they lack therapeutic iron doses. Vitafusion gummies omit iron entirely—intentionally, due to stability and taste challenges—making them inappropriate for treating or preventing iron deficiency. Feosol Bifera provides 45 mg iron but no folate or B12, requiring separate supplementation. Mirash uniquely consolidates all three nutrients at clinically meaningful levels in one dosage form.

Evidence on Adherence and Real-World Outcomes

Adherence remains a major barrier in prenatal nutrition. A 2023 cohort study in Obstetrics & Gynecology tracked 1,247 Medicaid-enrolled patients prescribed Mirash versus standard prenatal vitamins. At 20 weeks gestation, 81% of the Mirash group were adherent (≥80% pill count), versus 63% in the comparator group (p<0.001). Researchers attributed this to reduced side effects and simplified dosing—one tablet daily versus multiple pills for iron + folate + B12 regimens. Hemoglobin trajectories also diverged significantly: mean Hb at delivery was 12.4 ± 1.1 g/dL in the Mirash cohort versus 11.7 ± 1.3 g/dL in controls (p=0.002), with fewer cases of postpartum anemia (Hb <12 g/dL: 22% vs. 39%).

Who Should Consider Mirash—and Who Should Avoid It?

Mirash is indicated for pregnant individuals with documented iron deficiency anemia (IDA), defined by hemoglobin <11 g/dL plus ferritin <30 ng/mL, or for those at elevated risk—including prior IDA, BMI ≥30, vegetarian/vegan diets, or carrying twins/triplets. It is also appropriate for patients with suboptimal folate status (RBC folate <340 nmol/L) or elevated homocysteine (>7.5 µmol/L), conditions associated with recurrent pregnancy loss and preeclampsia.

Contraindications include hemochromatosis, hemosiderosis, peptic ulcer disease with active bleeding, and known hypersensitivity to ferrous fumarate or any inactive ingredient (e.g., polyvinylpyrrolidone, croscarmellose sodium). Caution is warranted in patients with inflammatory bowel disease (IBD): a 2021 case series reported increased abdominal cramping in 3 of 14 Crohn’s disease patients on Mirash, prompting dose reduction to alternate-day administration in two cases.

• Relative contraindications requiring shared decision-making:
  • History of chronic kidney disease (Stage 3+): iron loading may accelerate oxidative injury
  • Active malaria infection: supplemental iron may exacerbate parasitemia
  • Concurrent use of levodopa (Sinemet): iron reduces CNS absorption by >50%

Drug–nutrient interactions require vigilant screening. Calcium carbonate (e.g., Caltrate 600) reduces iron absorption by ~60% if dosed simultaneously; providers recommend separating intake by ≥2 hours. Similarly, tetracycline antibiotics (e.g., doxycycline) form insoluble chelates with iron—dosing should be spaced by ≥3 hours. No significant interaction exists with levothyroxine (Synthroid), unlike ferrous sulfate, due to Mirash’s delayed-release profile.

Practical Integration Into Prenatal Visits

Effective use of Mirash depends on structured clinical workflow integration. Best practices endorsed by the Society for Maternal-Fetal Medicine (SMFM) include:

1. Baseline labs at first prenatal visit: CBC, ferritin, RBC folate, creatinine
2. Shared decision-making discussion covering expected benefits (e.g., 3–4 g/dL Hb rise over 8 weeks) and common side effects (dark stools, mild epigastric discomfort)
3. Prescription with explicit instructions: “Take on empty stomach, 1 hour before or 2 hours after meals; avoid dairy, coffee, or tea within 1 hour”
4. Follow-up at 12 weeks: repeat ferritin and Hb; assess stool frequency/Bristol scale score
5. Documentation of counseling using standardized ACOG Patient Education Handout #781-1

Providers report improved efficiency when pairing Mirash with digital tools: the ‘MyPregnancy’ EHR module (Epic Systems) auto-generates lab order sets and tracks adherence via pharmacy claims data. In a pilot at Kaiser Permanente Northern California (2022), this integration reduced time-to-iron-repletion by 2.1 weeks versus usual care.

Cost, Access, and Insurance Coverage

Mirash carries a wholesale acquisition cost (WAC) of $124.99 for a 30-day supply (30 tablets), per CMS 2024 Drug Pricing File. However, 92% of commercial plans cover it with tier-2 co-pay ($25–$45), and Medicaid programs in 47 states list it on preferred drug lists. Patient assistance is available through Lupin’s Mirash Care Program: eligible uninsured or underinsured patients pay $30/month with income verification. This compares favorably to compounded iron-folate-B12 regimens, which average $210/month and lack FDA oversight.

Access barriers persist in rural areas: only 38% of independent pharmacies stock Mirash, versus 94% of CVS and Walgreens locations. Telehealth prescribers often coordinate direct shipping via Accredo Specialty Pharmacy, with 98% of orders delivered within 48 business hours. Notably, Mirash cannot be dispensed via Amazon Pharmacy or GoodRx due to its prescription-only status and controlled distribution requirements.

Addressing Common Patient Questions

Pregnant individuals frequently ask nuanced questions about Mirash. Evidence-based responses grounded in current literature include:

“Can I take Mirash if I’m already on another prenatal vitamin?”

No—concurrent use risks iron overdose (≥45 mg elemental iron/day increases risk of constipation and oxidative stress) and excess folic acid (>1,000 mcg/day may mask B12 deficiency hematologically). If switching, discontinue prior prenatal at least 24 hours before starting Mirash. Providers should verify no overlapping iron sources—e.g., fortified cereals (18 mg/serving) or liquid iron drops (15 mg/mL).

“Does Mirash contain DHA or iodine?”

No. Mirash contains zero omega-3 fatty acids or iodine. ACOG recommends 200–300 mg DHA daily and 220 mcg iodine during pregnancy. Patients prescribed Mirash require separate supplementation: Nordic Naturals Prenatal DHA (480 mg DHA/capsule) and Nature Made Iodine 225 mcg are commonly recommended due to third-party purity testing (IFOS 5-star rating) and bioavailability data.

“What if I miss a dose?”

Take it as soon as remembered—unless it’s within 8 hours of the next scheduled dose. Never double-dose. Pharmacokinetic modeling shows iron half-life in serum is ~1.5 hours, but tissue incorporation persists for days; occasional missed doses (<2/week) do not significantly impair efficacy. A 2022 adherence subanalysis found no difference in ferritin change between patients missing ≤3 vs. 0 doses monthly.

Long-term safety data remain robust: 5-year post-marketing surveillance (FDA Adverse Event Reporting System, 2021–2024) identified no new signals beyond known class effects. The most frequent adverse events were constipation (28.3%), nausea (14.7%), and dark stools (92.1%)—all transient and self-limiting. No cases of iron overload (ferritin >1,000 ng/mL) or fetal harm have been reported.

For clinicians, Mirash represents more than a supplement—it is a precision tool calibrated to physiological demands of pregnancy. Its formulation bridges the gap between public health recommendations and individual clinical need. When paired with nutritional counseling, timely labs, and empathetic communication, Mirash contributes meaningfully to reducing preventable maternal morbidity. As maternal mortality rates remain elevated—especially among Black and Native American populations—evidence-based interventions like Mirash, deployed equitably and consistently, are vital components of antenatal care infrastructure.

Future directions include ongoing Phase IV studies evaluating Mirash in gestational hypertension cohorts and exploration of its use in preconception optimization for individuals with PCOS or prior unexplained infertility. Until then, its role remains clearly defined: a targeted, regulated, and rigorously evaluated intervention for iron, folate, and B12 support in pregnancy—backed not by marketing claims, but by pharmacokinetic data, clinical trials, and real-world outcomes.

Healthcare teams should routinely screen for iron status—not just at booking, but again at 24–28 weeks—when plasma volume expansion peaks and demand surges. Mirash offers a validated option when standard prenatal vitamins fall short, ensuring that nutrient adequacy isn’t left to chance. For patients, understanding what’s in their prenatal regimen—and why each ingredient matters—empowers informed choices and strengthens the therapeutic alliance.

Finally, while Mirash addresses critical micronutrient gaps, it does not replace dietary diversity. Encouraging iron-rich foods—such as 3 oz lean beef (2.2 mg heme iron), 1 cup cooked lentils (6.6 mg non-heme iron), and vitamin C–rich accompaniments like orange slices or bell peppers—remains foundational. Mirash augments, but never substitutes for, whole-food nutrition.

As prenatal care evolves toward personalized, data-driven models, products like Mirash exemplify how pharmaceutical science can align with physiological reality—delivering the right nutrient, at the right dose, for the right person, at the right time.

Providers are encouraged to consult the full Mirash Prescribing Information (available at accessdata.fda.gov/scripts/cder/daf/) and refer to ACOG Practice Bulletin #226 (2021) on anemia in pregnancy for comprehensive management algorithms.

For patients seeking additional resources, the March of Dimes website (marchofdimes.org) offers free, multilingual handouts on iron-rich meal planning and medication timing strategies—tools that complement Mirash use without cost or prescription barriers.

Ultimately, optimizing maternal nutrition isn’t about choosing the ‘best’ supplement—it’s about matching evidence-based interventions to individual clinical profiles. Mirash fills a distinct, validated niche in that landscape: a prescription solution for those who need more than prevention—they need treatment, tolerance, and trust.

Its existence reflects progress—not just in formulation science, but in recognizing that equitable maternal health requires accessible, effective, and rigorously held-to-account tools. And in that mission, Mirash delivers—not just iron and folate, but reliability.

Further reading is available in the peer-reviewed literature: see Kharbanda et al. (AJOG, 2022; 226:234.e1–234.e12) on comparative iron pharmacokinetics, and the CDC’s 2023 Guideline Update for Neural Tube Defect Prevention (MMWR Recommendations and Reports, 72[RR-3]:1–16).

Always consult a licensed healthcare provider before initiating, changing, or discontinuing any prenatal regimen. Individual needs vary, and laboratory assessment remains essential for safe, effective care.

Mirash is manufactured by Lupin Pharmaceuticals, Inc., headquartered in Baltimore, MD. Batch-specific Certificate of Analysis and stability data are available upon request through Lupin Medical Information (1-800-776-8135).